# US 5,352,665 A · Method of treating disease caused by the infection of virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,352,665 A
- Document ID: US5352665A
- Status: Granted
- Kind: A
- Application number: 08/091,745
- Filed: 1993-07-15
- Granted: 1994-10-04
- Earliest claimed: 1987-11-24
- Assignees: Mitsui Toatsu Chemicals, Inc.
- Inventors: Akira Awaya; Hisashi Kobayashi; Yusaku Ishizuka; Hayao Abe
- Web page: https://patentgrep.com/patent/US5352665A

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A medicament for prevention and remedy of diseases caused by the infection of viruses is disclosed, which is characterized by containing as an effective ingredient thereof a nonapeptide having the following amino acid configuration: pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn or an ester and an amide at the carboxyl group of the C-terminal of the asparagine or a pharmacologically acceptable salt thereof.

## Claims

### Claim 1

A method of treating a vital infection in an animal consisting essentially of administering to the animal an anti-viral effective amount of a nonapeptide devoid of zinc and having the amino acid sequence:
pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn
or an ester and an amide at the carboxyl group of the C-terminal of the asparagine or a pharmacologically acceptable salt thereof,
wherein the viral infection is caused by a virus causing diabetes, a digestive disorder, a respiratory disorder or a cerebronervous disorder, and said virus is selected from the group consisting of REO virus, pig Aujeszky's disease virus, hepatitis virus, human T-lymphocyte virus type I, human T-lymphocyte virus type II and human T-lymphocyte virus type III.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the digestive disorder is hepatitis.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the virus is REO virus.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the virus is pig Aujeszky's disease virus.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the virus is hepatitis virus.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the virus is human T-lymphocyte virus type I.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the virus is human T-lymphocyte virus type II.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the virus is human T-lymphocyte virus type III.